INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Paper

Antiviral Drug Discovery: From Traditional Screening to Modern Computational Approaches

Prof. Kaufiya sayyad, Shreya kawade*, Priya Rathod, Premkumar Naubade Devanand Jadhav, Anchal kshirsagar

Department of Pharmacy at Godavari institute of pharmacy kolpa, Latur 413512, Maharashtra, India.

ARTICLE INFO

Published: 25 Apr 2026
Keywords:
Antiviral agents, drug discovery, viral targets, resistance, host-directed therapy, RNA viruses.
DOI:
10.5281/zenodo.19758946

ABSTRACT

Clinically approved antiviral drugs are currently available for only a small fraction of the more than 220 viruses known to infect humans. The rapid spread of viral infections such as HIV, influenza, hepatitis, and SARS-CoV-2 has highlighted the urgent need for new antiviral therapeutics. Antiviral drug discovery involves identifying viral or host targets essential for replication and designing molecules that inhibit them. This review summarizes the key approaches to antiviral drug discovery, major classes of antiviral drugs, viral targets, current challenges including drug resistance, and the prospects of modern drug discovery technologies such as computational design, high-throughput screening, and host-targeted therapies. Antiviral drug discovery has become an increasingly vital area of biomedical research, especially in the wake of emerging and re-emerging viral infections such as COVID-19, Ebola, and Zika. Despite over 220 known human-infecting viruses, clinically approved antiviral drugs are currently available for only a limited number of viral diseases, including HIV, hepatitis, influenza, and herpesvirus infections. The discovery process involves identifying viral or host targets essential for replication and developing molecules that inhibit these processes without causing host toxicity. Traditional drug discovery strategies, including target-based screening, structure-based drug design, and repurposing of existing drugs, have been complemented by novel approaches such as high-throughput screening, computational modeling, and artificial intelligence-driven discovery. Additionally, host-directed therapies and broad-spectrum antivirals have gained attention due to their potential to overcome viral mutation and resistance. However, challenges such as viral diversity, high mutation rates, and limited understanding of virus-host interactions continue to hinder progress. The integration of omics technologies, bioinformatics, and rational drug design offers promising avenues to accelerate antiviral development and prepare for future viral pandemics.

***Corresponding Author:** Shreya kawade
Address: *Department of Pharmacy at Godavari institute of pharmacy kolpa, Latur 413512, Maharashtra, India*
Email ✉: kawadeshreya488@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

INTRODUCTION

Viral infections are among the most challenging diseases to treat due to the intracellular nature of viruses and their rapid mutation rates. Unlike bacteria, viruses depend on the host cell machinery for replication, making it difficult to identify selective antiviral targets. The discovery of antiviral drugs began with the introduction of idoxuridine against herpesvirus in the 1960s and expanded significantly with the development of antiretroviral therapy (ART) for HIV. Despite advancements, clinically effective antivirals exist for only a limited number of viruses, emphasizing the need for innovative drug discovery approaches. Here's a sample introduction section for a review paper on "Antiviral Drugs Discovery", written in a scientific and academic style, complete with relevant references (APA style) you can Viral infections continue to pose a significant threat to global public health, contributing to considerable morbidity and mortality worldwide. Despite the availability of effective vaccines for several viral pathogens, there remains a pressing need for antiviral drugs, especially for emerging and re-emerging viruses that lack preventive measures. The discovery and development of antiviral drugs have evolved substantially over the past decades, leading to the successful management of infections such as HIV, hepatitis B and C, influenza, and herpes simplex virus. However, of the more than 220 viruses known to infect humans, clinically approved antiviral therapies exist for only about 10 viral families, highlighting the substantial gap in therapeutic coverage. The outbreak of SARS-CoV-2 further emphasized the urgent necessity for broad-spectrum antiviral agents that can be rapidly deployed against novel or re-emerging viral pathogens. Traditional antiviral discovery approaches—focused mainly on viral enzymes and replication pathways—are increasingly being complemented by host-targeted strategies and computational drug design methods. Advances in molecular virology, high-throughput screening, and structure-based drug design have accelerated the identification of potential antiviral targets and compounds with improved efficacy and safety profiles .None the less, antiviral drug development faces persistent challenges, including viral mutation leading to drug resistance, toxicity, and the complexity of host–virus interactions. Addressing these challenges requires integrated multidisciplinary strategies combining virology, bioinformatics, medicinal chemistry, and pharmacology to facilitate the discovery of next-generation antiviral therapeutics . This review aims to provide an overview of the current landscape of antiviral drug discovery, the major strategies employed, and the future perspectives in developing effective antivirals against existing and emerging viral threats.

Approaches to Antiviral Drug Discovery

Target-Based Drug Discovery:

This approach focuses on identifying specific viral enzymes or proteins essential for replication. Examples include:

Reverse Transcriptase inhibitors (e.g., Zidovudine for HIV)

Protease inhibitors (e.g., Ritonavir)

RNA polymerase inhibitors (e.g., Remdesivir for SARS-CoV-2)



Fig no.1 Target-Based Drug Discovery

Phenotypic Screening

In this method, compounds are tested for antiviral activity without prior knowledge of the molecular target. Hits are later optimized and the mechanism of action is elucidated. Screening compounds in cell-based (or organism-based) systems to look for desired effects (such as reduction in viral infection or cytopathic effect), without necessarily knowing the molecular target in advance. Contrasts with target-based screening where one has a predefined viral or host target (enzyme, receptor, etc.)

Structure-Based Drug Design

Advancements in X-ray crystallography and cryo-electron microscopy allow detailed visualization of viral protein structures, enabling rational drug design. This approach was used in developing neuraminidase inhibitors (Oseltamivir) for influenza. Structure-based drug design (SBDD) is a rational approach to drug discovery that utilizes the 3D structure of a target biomolecule, often obtained through X-ray crystallography, cryo-electron microscopy (cryo-EM), or NMR spectroscopy. The primary goal is to design or optimize small molecules that can bind to the active or allosteric site of a biological target, thereby modulating its function.

Key steps in SBDD

Target structure determination
Binding site identification
Ligand design and optimization
Molecular docking
Scoring and banking
Molecular dynamics

Host-Directed Therapy

Instead of targeting the virus directly, these drugs modulate host factors required for viral replication. This reduces the likelihood of resistance but may increase toxicity. Host-directed therapy (HDT) refers to therapeutic strategies that target host cellular pathways exploited by viruses for entry, replication, assembly, or immune evasion. Unlike direct-acting antivirals (DAAs), which target viral proteins, HDTs focus on modulating host factors, potentially offering broad-spectrum activity and reducing the likelihood of resistance due to viral mutations.

Rationale for HDT in Antiviral Therapy

Viruses are obligate intracellular pathogens that hijack host machinery.

Targeting conserved host pathways can provide broad-spectrum antiviral effects.

Less prone to resistance compared to DAAs, which often face escape mutations.

Can be used in combination with DAAs to enhance efficacy and durability.

Table No. 1 Major Classes of Antiviral Drugs

Drug Class	Mechanism of Action	Example
Nucleoside/Nucleotide analogues	Inhibit viral polymerase	Acyclovir, Zidovudine
Protease inhibitors	Block viral protein processing	Ritonavir, Lopinavir
Neuraminidase inhibitors	Prevent viral release	Oseltamivir , Zanamivir
Entry/Fusion inhibitors	Block viral entry into host cell	Enfuvirtide, Maraviroc
Integrase inhibitors	Prevent integration of viral DNA	Raltegravir

Challenges in Antiviral Drug Discovery

The discovery and development of antiviral drugs remain among the most complex and resource-intensive areas of pharmaceutical research. Despite significant progress since the advent of nucleoside analogs and protease inhibitors, multiple challenges hinder the development of safe, effective, and broadly acting antivirals.

Viral Diversity and Mutation Rates

Viruses exhibit immense genetic diversity and rapid mutation rates, especially RNA viruses such as HIV, influenza, and SARS-CoV-2. These mutations lead to drug resistance and escape from immune or drug pressure, reducing the long-term efficacy of antiviral agents.

Dependence on Host Machinery

Most viruses rely heavily on host cellular machinery for replication. This dependence limits the number of virus-specific drug targets and raises the risk of host toxicity when targeting shared pathways. Developing host-targeted antivirals that selectively modulate viral replication without significant cytotoxicity remains a major challenge.

Limited Structural Information

Many viral proteins are unstable, membrane-bound, or short-lived, making them difficult to crystallize and characterize structurally. The lack of high-resolution structures impedes structure-based drug design approaches (Kumar et al., 2020).

Emergence of Drug Resistance

Continuous viral evolution often results in resistance mutations within the target enzyme or protein. Combination therapy has mitigated this issue in HIV and HCV, yet new resistance patterns continue to emerge.

Cross-species Transmission and Emerging Viruses

Zoonotic viruses such as Ebola, SARS, and Nipah emerge unpredictably, and their biology is often poorly understood during outbreaks. The lack of pre-existing platforms and screening models delays antiviral discovery during pandemics.

Limitations in Preclinical Models

Current in vitro and animal models often fail to accurately replicate human viral pathogenesis. This mismatch leads to poor translation of preclinical efficacy to clinical outcomes. Preclinical studies form the foundation for evaluating the safety, efficacy, and

pharmacokinetic profile of antiviral drug candidates before clinical trials. However, several limitations in current in vitro and in vivo models hinder the translation of preclinical findings to successful clinical outcomes.

Regulatory and Economic Barriers

Antiviral drug development involves high R&D costs, stringent regulatory requirements, and a limited market return once viral outbreaks subside. These factors disincentivize pharmaceutical companies from investing in broad-spectrum or rare-virus antivirals.

Modern Strategies and Future Perspectives

Computational Drug Design

In silico modeling, docking, and molecular dynamics simulations accelerate the identification of potential inhibitors before synthesis.

High-Throughput Screening (HTS)

Automated HTS allows rapid testing of thousands of compounds for antiviral activity.

Artificial Intelligence and Machine Learning

AI models predict active antiviral molecules and analyze viral mutation patterns to guide drug optimization.

Broad-Spectrum Antivirals

Efforts are ongoing to develop antivirals targeting conserved viral processes or host factors, offering protection against multiple viruses.



Fig.no.2 Modern Strategies and Future Perspectives

CONCLUSION

Antiviral drug discovery is a dynamic and evolving field, driven by advances in molecular biology, genomics, and computational technology. The integration of structure-based design, host-directed therapy, and AI-driven discovery has the potential to revolutionize the development of effective, broad-spectrum antiviral agents. Continued global collaboration between academia, industry, and public health sectors is crucial for preparing against future viral pandemics. Antiviral drug discovery remains one of the most complex yet crucial areas in modern pharmacology. Despite remarkable progress in understanding viral biology and host–virus interactions, the rapid mutation rates, emergence of resistant strains, and limited druggable viral targets continue to challenge researchers. Advances in structure-based drug design, high-throughput screening, computational modeling, and omics technologies have accelerated the identification of novel antiviral compounds. Moreover, the development of broad-spectrum antivirals and host-targeted

therapies offers promising strategies to overcome viral resistance. Collaborative global research efforts, integration of artificial intelligence, and investment in pandemic preparedness are essential to achieving long-term success in this field. Continued innovation and interdisciplinary approaches will be key to translating scientific discoveries into effective, safe, and accessible antiviral therapies worldwide

REFERENCES

1. De Clercq, E., & Li, G. (2016). Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews, 29(3), 695–747.
2. De Clercq, E., & Li, G. (2016). Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews, 29(3), 695–747. https://doi.org/10.1128/CMR.00102-15
3. Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K. Y. (2016). Coronaviruses — drug discovery and therapeutic options. Nature Reviews Drug Discovery, 15(5), 327–347. https://doi.org/10.1038/nrd.2015.37
4. Pushpakom, S., et al. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews Drug Discovery, 18(1), 41–58. https://doi.org/10.1038/nrd.2018.168
5. Bekerman, E., & Einav, S. (2015). Combating emerging viral threats. Science, 348(6232), 282–283. https://doi.org/10.1126/science.aaa3778
6. De Clercq, E., & Li, G. (2016). Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews, 29(3), 695–747. https://doi.org/10.1128/CMR.00102-15
7. Proudfoot, A. I., Bayly, A. R., & Kellam, P. (2021). Antiviral drug discovery: New approaches for an old problem. Frontiers in Virology, 1, 723. https://doi.org/10.3389/fviro.2021.723
8. Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K. Y. (2016). Coronaviruses—drug discovery and therapeutic options. Nature Reviews Drug Discovery, 15(5), 327–347. https://doi.org/10.1038/nrd.2015.37
9. Zumla, A., Hui, D. S., Perlman, S., & Maeurer, M. (2020). Reducing mortality and morbidity in patients with severe COVID-19 infection by early recognition and intervention. The Lancet Infectious Diseases, 20(5), e117–e125. https://doi.org/10.1016/S1473-3099(20)30211-7
10. Ianevski, A., Yao, R., & Zusinaite, E. (2020). Novel antiviral strategies and drug discovery approaches. Microorganisms, 8(6), 850. https://doi.org/10.3390/microorganisms8060850
11. Rietdijk J., Tampere M., Pettke A., et al. “A phenomics approach for antiviral drug discovery.” BMC Biology 2021. DOI:10.1186/s12915-021-01086-1.
12. . Jia H., Hu L., Zhang J., Huang X., et al. “Recent advances of phenotypic screening strategies in the application of anti-influenza virus drug discovery.” RSC Medicinal Chemistry, 2024
13. Martinez, J. P., Sasse, F., Brönstrup, M., Diez, J., & Meyerhans, A. (2015). Antiviral drug discovery: Broad-spectrum drugs from nature. Natural Product Reports, 32(1), 29–48. https://doi.org/10.1039/C4NP00085D
14. Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016). Coronaviruses—drug discovery and therapeutic options. Nature Reviews Drug Discovery, 15(5), 327–347.
15. Agostini, M. L., et al. (2018). Coronavirus susceptibility to antiviral remdesivir is mediated by the viral polymerase. mBio, 9(2), e00221-18.

16. Pizzorno, A., Padey, B., Terrier, O., & Rosa-Calatrava, M. (2019). Drug repurposing approaches for the treatment of influenza and coronaviruses. Frontiers in Immunology, 10, 741.
17. Das, K., Arnold, E., & De Clercq, E. (2021). Antiviral drug discovery: advances and challenges. Nature Reviews Drug Discovery, 20(6), 385–386.
18. De Clercq, E., & Li, G. (2016). Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews, 29(3), 695–747.
19. Ianevski, A., Zusinaite, E., & Kainov, D. E. (2019). Novel functional signatures in antiviral drug screening. Viruses, 11(2), 151.
20. Kang, S., et al. (2022). Recent advances in antiviral drug discovery. ACS Infectious Diseases, 8(4), 787–804.
21. Kumar, N., Sharma, N. R., Ly, H., & Parslow, T. G. (2020). Advances in antiviral drug discovery against RNA viruses. International Journal of Molecular Sciences, 21(14), 5073.
22. Pawlotsky, J. M. (2016). Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology, 151(1), 70–86.
23. Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K. Y. (2016). Coronaviruses — drug discovery and therapeutic options. Nature Reviews Drug Discovery, 15(5), 327–347.
24. Zumla, A., & Hui, D. S. (2020). Emerging and re-emerging viral infections: Advances in antiviral therapy. Lancet Infectious Diseases, 20(1), e9–e10.
25. De Clercq, E., & Li, G. (2016). Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews, 29(3), 695–747.
26. Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K. Y. (2016). Coronaviruses drug discovery and therapeutic options. Nature Reviews Drug Discovery, 15(5), 327–347.
27. Mercorelli, B., Palù, G., & Loregian, A. (2018). Drug repurposing for viral infectious diseases: How far are we? Trends in Microbiology, 26(10), 865–876.
28. ingh, K., & Kumar, A. (2021). Recent advances in antiviral drug discovery: Current challenges and future prospects. Current Pharmaceutical Design, 27(24), 2802

HOW TO CITE: Prof. Kaufiya sayyad, Shreya kawade, Priya Rathod, Premkumar Naubade Devanand Jadhav, Anchal kshirsagar, Antiviral Drug Discovery: From Traditional Screening to Modern Computational Approaches, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 4206-4212, https://doi.org/10.5281/zenodo.19758946